BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs4950928
,
VEGFA
,
Coagulation
,
Obesity
,
Liver
,
Neocentromeres
,
Rapamycin
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
map2k1 protein human
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
SK-MEL-28 melanoma cells with anthrax lethal toxin-induced knockdown of MEK1 and MEK2
PAR-2 activation in pancreatic cancer cell line BxPC-3
Explore Curated Studies Results
Literature
Most Relevant Literature
Histiocytic neoplasm subtypes differ in their MAP2K1 mutational type.
Sclerosing melanocytic tumors with MAP2K1 in-frame deletions and copy number gains in 15q: A distinc…
Late moyamoya-like angiopathy syndrome revealing MAP2K1 Noonan syndrome.
Classic hairy cell leukemia with MAP2K1 mutation: a case report].
Clinical, Morphologic, and Molecular Features of Benign and Intermediate-grade Melanocytic Tumors Wi…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Lan…
Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Dis…
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS W…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ